Fjarde AP Fonden Fourth Swedish National Pension Fund Has $5.84 Million Stake in Zimmer Biomet Holdings, Inc. (ZBH)

Fjarde AP Fonden Fourth Swedish National Pension Fund lifted its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 5.5% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 49,853 shares of the medical equipment provider’s stock after acquiring an additional 2,619 shares during the period. Fjarde AP Fonden Fourth Swedish National Pension Fund’s holdings in Zimmer Biomet Holdings were worth $5,837,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the company. BlackRock Inc. boosted its holdings in shares of Zimmer Biomet Holdings by 4.1% in the second quarter. BlackRock Inc. now owns 17,419,463 shares of the medical equipment provider’s stock worth $2,236,657,000 after acquiring an additional 679,080 shares during the period. Vanguard Group Inc. boosted its stake in Zimmer Biomet Holdings by 2.6% during the second quarter. Vanguard Group Inc. now owns 13,380,517 shares of the medical equipment provider’s stock valued at $1,718,057,000 after buying an additional 339,106 shares during the period. Longview Partners Guernsey LTD boosted its stake in Zimmer Biomet Holdings by 17.7% during the third quarter. Longview Partners Guernsey LTD now owns 7,506,684 shares of the medical equipment provider’s stock valued at $878,958,000 after buying an additional 1,128,973 shares during the period. American Century Companies Inc. boosted its stake in Zimmer Biomet Holdings by 8.1% during the third quarter. American Century Companies Inc. now owns 4,165,353 shares of the medical equipment provider’s stock valued at $487,721,000 after buying an additional 311,654 shares during the period. Finally, Northern Trust Corp boosted its stake in Zimmer Biomet Holdings by 20.2% during the second quarter. Northern Trust Corp now owns 4,010,274 shares of the medical equipment provider’s stock valued at $514,919,000 after buying an additional 673,079 shares during the period. 85.44% of the stock is owned by hedge funds and other institutional investors.

Zimmer Biomet Holdings, Inc. (NYSE ZBH) traded up $1.16 during mid-day trading on Friday, hitting $112.24. The company’s stock had a trading volume of 1,631,900 shares, compared to its average volume of 1,366,117. Zimmer Biomet Holdings, Inc. has a 1 year low of $98.20 and a 1 year high of $133.49. The company has a debt-to-equity ratio of 0.88, a current ratio of 1.47 and a quick ratio of 0.78. The stock has a market cap of $22,490.71, a P/E ratio of 13.77, a price-to-earnings-growth ratio of 1.72 and a beta of 1.17.

Zimmer Biomet Holdings (NYSE:ZBH) last posted its earnings results on Wednesday, November 1st. The medical equipment provider reported $1.72 earnings per share for the quarter, missing analysts’ consensus estimates of $1.74 by ($0.02). Zimmer Biomet Holdings had a return on equity of 16.29% and a net margin of 8.36%. The firm had revenue of $1.82 billion for the quarter, compared to analysts’ expectations of $1.83 billion. During the same quarter last year, the company posted $1.79 EPS. The firm’s revenue was down .8% on a year-over-year basis. research analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.03 earnings per share for the current year.

Several equities research analysts recently issued reports on ZBH shares. BidaskClub lowered Zimmer Biomet Holdings from a “buy” rating to a “hold” rating in a research note on Monday, July 24th. Cantor Fitzgerald set a $137.00 price objective on Zimmer Biomet Holdings and gave the company a “hold” rating in a research note on Thursday, July 27th. Canaccord Genuity lowered Zimmer Biomet Holdings from a “buy” rating to a “hold” rating and dropped their price objective for the company from $141.00 to $135.00 in a research note on Friday, July 28th. Piper Jaffray Companies reissued a “buy” rating and set a $135.00 price objective on shares of Zimmer Biomet Holdings in a research note on Friday, July 28th. Finally, Oppenheimer Holdings, Inc. set a $137.00 price objective on Zimmer Biomet Holdings and gave the company a “buy” rating in a research note on Friday, July 28th. Four analysts have rated the stock with a sell rating, seven have issued a hold rating, fourteen have given a buy rating and one has given a strong buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average price target of $133.71.

WARNING: This piece of content was originally published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of US and international copyright law. The correct version of this piece of content can be viewed at https://ledgergazette.com/2017/11/17/fjarde-ap-fonden-fourth-swedish-national-pension-fund-has-5-84-million-stake-in-zimmer-biomet-holdings-inc-zbh.html.

Zimmer Biomet Holdings Company Profile

Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Institutional Ownership by Quarter for Zimmer Biomet Holdings (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply